Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
27 Items
Title  Creator  Group name  Publishing year 
Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe. Tabet et al. EquipeCTCS 2025
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer Orhan et al. EquipeCTCS 2024-05-01
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib Velazquez et al. EquipeMY 2023
Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry Vezzio-Vié et al. EquipeCTCS 2022-05-20
Multi-Level Control of the ATM/ATR-CHK1 Axis by the Transcription Factor E4F1 in Triple-Negative Breast Cancer Batnini et al. EquipeCTCS 2022-08-16
In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2 du Manoir et al. EquipeCTCS 2022-07
Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy? Orhan et al. EquipeCTCS 2021-06-11
MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis Kantar et al. EquipeAM 12/2021
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models Rabia et al. EquipeCG 2021 Jan-Dec
Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma Cissé et al. EquipeLLC 2020-06-10
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer Jacot et al. EquipeMY 2020-03-30
A predictable conserved DNA base composition signature defines human core DNA replication origins Akerman et al. EquipeCTCS 2020-09-21
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data Chartron et al. EquipeELC Jan 2019
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Ashraf et al. EquipeAT Feb 04, 2019
Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells Fonti et al. EquipeCTCS Sep 01, 2019
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer Bourillon et al. EquipeELC 2019-10-01
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis Leconet et al. EquipeCG Jun 01, 2017
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium Obermayr et al. EquipeCTCS Dec 05, 2017
Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition Arnould et al. PlateformeRHEM 2017-11-10
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer Kreuzinger et al. EquipeCTCS Dec 15, 2017
TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion Chevalier et al. EquipeMY Feb 22, 2016
Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care El Messaoudi et al. EquipeCTCS 06 15, 2016
Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations? Jacot et al. EquipeELC 2015
Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure Colombo et al. EquipeMY Sep 29, 2015
Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells Bach et al. EquipeELC Sep 29, 2015
12>>>
27 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés